

Contents

Preface *xiii*

Part I Optimizing Pharmacokinetics in Discovery 1

1	The Importance of Pharmacokinetics in Early Drug Discovery	3
1.1	PK as a Surrogate for Efficacy	3
1.2	The Many Faces of Pharmacokineticists	6
1.3	The Criteria for Good PK of a Therapeutically Useful Drug	9
1.4	The Goals of Early Discovery	10
	References	13
2	In Search of “Good” Pharmacokinetics	15
2.1	Describing the Concentration-time Profile	16
2.2	Half-life ($T_{1/2}$)	20
2.3	Area Under the Curve (AUC)	24
2.4	Biphasic PK Parameters	28
2.5	Constant Intravenous Infusion PK	32
2.6	Extravascular PK	33
2.7	Repeat-dose PK	37
2.8	Using Secondary PK Parameters to Guide Compound Selection	44
2.9	Practical Considerations of Conducting In Vivo PK Studies	49
	References	52
3	Linking Descriptive Pharmacokinetics to Underlying ADME Processes	55
3.1	The Body as Compartments: Exponential Time Courses Explained	57
3.2	Relating Descriptive PK Parameters to the Underlying ADME Process	66
3.3	Using Primary PK Parameters to Identify ADME Liabilities	74
3.4	Volume of Distribution and Clearance for Compounds with Biphasic PK	77
3.5	Conversion Between Blood, Plasma, and Unbound PK Parameters	82
3.6	Ranges of PK Parameters	85
3.7	Using Primary PK Parameters to Guide Compound Selection	87
3.8	Linking Primary PK Parameters to Intrinsic Compound Properties	97
	References	98

4	Mechanistic Basis of Distribution	101
4.1	Overview of Distribution Process	101
4.2	Factors Affecting Extent of Distribution	101
4.3	Using Volume of Distribution to Guide Drug Design and Selection	109
4.4	Mechanistic Basis of Biphasic PK	112
4.5	Using Rate of Distribution to Guide Lead Optimization	121
4.6	Mechanistic Basis of Plasma Protein Binding	122
	References	124
5	Mechanistic Basis of Clearance	127
5.1	Liver Metabolism as the Primary Clearance Pathway	128
5.2	Mechanistic Basis of Hepatic Metabolic Clearance	129
5.3	Applications of Clearance Concept in Drug Discovery	136
5.4	Other Routes of Elimination	144
5.5	Identifying the Rate-limiting Clearance Mechanisms	151
5.6	Drug–Drug Interaction and Metabolism Considerations	152
	References	153
6	Mechanistic Basis of Absorption	159
6.1	Overview of the Absorption Process	160
6.2	Factors Affecting Fraction Absorbed	161
6.3	First Pass Extraction	169
6.4	Interplay Between Absorption, First-pass Elimination, and Transporters	173
6.5	Applications of Absorption Concepts in Drug Discovery	174
6.6	Effect of Food on Oral Bioavailability	181
6.7	Lymphatic Absorption of Lipophilic Compounds	182
	References	184
7	Integrated Pharmacokinetic Analysis in Discovery	189
7.1	Integration of PK Concepts: A Road Map	189
7.2	Is Plasma Protein Binding Important?	194
7.3	How Potent Is Enough to Elicit Efficacy In Vivo?	197
7.4	Compounds/Series Selection	199
7.5	Drug Design	207
7.6	Identify ADME Liabilities	208
7.7	Study Design	213
7.8	Physiologically Based Pharmacokinetic (PBPK) Modeling	220
	References	229
8	Pharmacokinetics of Therapeutic Antibodies and Derivatives	235
8.1	General PK Characteristics of mAbs	237
8.2	Absorption of Monoclonal Antibodies	239
8.3	Distribution of Monoclonal Antibodies	241
8.4	Clearance of Monoclonal Antibodies	244
8.5	PBPK Modeling for Monoclonal Antibodies	246
8.6	PK Screening and Optimization of Monoclonal Antibodies	250
	References	253

Part 2	From Pharmacokinetics to Efficacy	259
9	The Importance of Pharmacodynamics in Early Drug Discovery	261
9.1	The PK-PD Disconnect	262
9.2	The Three Pillars of PD	264
9.3	Experimental Approaches for Studying Pharmacological Effects	267
	References	269
10	Reaching the Site of Action	271
10.1	Free Drug Hypothesis	272
10.2	Asymmetry in Unbound Tissue and Systemic Concentration	273
10.3	Time-course of Unbound Concentration in Target Tissue	278
10.4	Tissue Disposition Considerations in Drug Discovery	286
10.5	Target Organs with Complex Structures	295
10.6	When Systemic PK Is Not the Main Driver for Tissue Exposure	299
10.7	Tissue Disposition for Therapeutic Antibodies	303
	References	304
11	Hitting a Moving Target	311
11.1	Concentration-response Relationships	311
11.2	Receptor Kinetics Theory	315
11.3	Agonism	317
11.4	Antagonism	319
11.5	Slow Association and Disassociation	320
11.6	Target Turnover	322
11.7	Irreversible Inactivation	325
11.8	Proteolysis Targeting Chimeras (PROTACs)	329
11.9	Bisubstrate Kinetics	330
11.10	Implications to Toxicological Effects	332
11.11	Monoclonal Antibodies Target Engagement	333
	References	337
12	The Tangled Web of Pharmacology	343
12.1	Fast Responding Processes	346
12.2	Slow Turnover Processes	346
12.3	Multistage Processes	354
12.4	Activation of Precursor	358
12.5	Tolerance and Resistance	363
12.6	Cell Growth and Death	367
12.7	Importance of Response Duration in Determining PK Endpoints	369
12.8	Monoclonal Antibodies	369
12.9	Complex and Novel Systems	371
12.10	Toxicodynamics	371
	References	372

13	Pharmacodynamics-informed Drug Discovery	375
13.1	Selection of Target, Modality, and Mode of Action	376
13.2	Compound Screening	378
13.3	Compound Optimization	384
13.4	Virtual Screening and Drug Design	385
13.5	Design and Interpretation of Pharmacology Studies	387
13.6	Model-informed Drug Discovery	395
	References	410
Part III Picking the Right Human Dose		413
14	Human Dose Prediction: An Overview	415
	References	420
15	Predicting Human Systemic Pharmacokinetics	421
15.1	Predicting Human Volumes of Distribution and Clearance	421
15.2	Predicting Human Oral Bioavailability	432
15.3	Predicting the Concentration-time Profile	437
15.4	When Prediction of Human Systemic PK Is Unimportant	439
15.5	Predicting Human PK for Monoclonal Antibodies	441
	References	442
16	Predicting Human Pharmacodynamics	447
16.1	Species Difference in Tissue Disposition	448
16.2	Species Differences in Target Engagement	449
16.3	Species Differences in the Behaviors of Pharmacology	456
	References	468
17	Integrated PK/PD Approaches to Human Dose Prediction	473
17.1	A Simple Example of Starting First-in-human Dose Calculation	475
17.2	PK/PD Model-based MABEL Determination	478
17.3	Evaluating Data Quality	493
17.4	Quantifying the Impact of Uncertainty on Decisions	499
	References	504
Appendix A: In Vitro ADME Assays		507
A.1	Permeability	507
A.2	Solubility and Dissolution	508
A.3	Plasma Protein Binding	509
A.4	Blood-to-plasma Ratio, <i>B:P</i>	510
A.5	Tissue Partitioning	510
A.6	Transporters	510
A.7	Intrinsic Metabolic Clearance (Stability)	511
A.8	CYP450 Phenotyping	511
A.9	CYP450 Inhibition	512
A.10	CYP450 Time-dependent Inhibition	513
	References	513

Appendix B: QSAR and QSPR Models 515

- B.1 What Are QSAR and QSPR Models? 515
- B.2 Model-building Process 515
- B.3 Molecular Descriptors 516
- B.4 Global Versus Local Models 516
- B.5 Types of Models 516
- B.6 Validation and Prediction 517
- References 517

Appendix C: Methods for Monitoring Tissue Concentrations 519**Appendix D: Anatomical and Physiological Parameters** 521

- D.1 Blood Flows 521
- D.2 Volumes of Organs and Body Fluids 522
- D.3 Intestinal Physiology 523
- D.4 Miscellaneous Properties 523
- References 524

Appendix E: Useful Equations 525

- E.1 Calculating Secondary PK Parameters from Concentration-time Data 525
- E.2 Calculating Primary PK Parameters from Secondary PK Parameters 526
- E.3 Conversions Between Plasma, Blood, and Unbound PK Parameters 527
- E.4 Calculating Primary PK Parameters from In Vitro or In Silico Data 527
- E.5 Calculating the Concentration-time Profile from Primary PK Parameters 528

Symbols and Abbreviations 531**Index** 537

